MDR/EU relatedPosted by Peter May 15, 2019 10:13:27
Medtech Europe have created a guidance document that discuss use of certain symbols like the Medical device symbol - MD-, devices that includes Different types of substances and translations etc. the documents can be found here
. These guidance are useful since you wiull know that many comnpanies will use it and hence the power behind this will be strong vs that you find symbols yourself. They have of coarse not just created them, but refers to different ISO standards.
General speakiong, using already existing standards are always better than create something yourself!
MDR/EU relatedPosted by Peter May 04, 2019 13:33:16
What does significant change mean in MDR. It is not described, but COCOR and Medtech Europe have created a position paper which you can find here
MDR/EU relatedPosted by Peter Apr 10, 2019 14:06:48
All manufacturers will soon be or are already effected by the MDR or IVDR. It is probably worst for the ones that have products reclassified from class I to IIa (see previously posts) but majority of companies are class I companies. These are also effected quire hard depending on how the run their operations today.
The big news for class I manufacturers are that they must have a almost complete quality management system. no need for certification, but when the authorities inspect the companies you better meet ISO 13485 to avoid issues.
Already now the authorities have started to send out letters to manufacturers about the changes. One example is the Swedish authority sending out letters
to the CEOs of class I registered products. Hopefully they read it carefully. The letter basically goes through article 10.9 in the regulation.
MDR/EU relatedPosted by Peter Apr 08, 2019 12:22:49
BSi have issued a document about their best practise when it comes to MDR. Considering that they are the first and only approved MDR notified body this is of coarse very interesting reading. Download your copy here
OtherPosted by Peter Apr 03, 2019 14:51:34
Did you know that from April 1st you must provide your invoices to public hospitals, communities and states electronically! This is an European requirement.
what is an E-invoice then? It is not a pdf copy of your normal paper invoice! It must meet the requirements in PEPPOL BIS Billing 3. Read more about the standard here
If you do public business better ask your system provider if they meet the requirements, if not you must act now!
The new requirements are valid for new tenders or direct buy and hence not valid for tender that was won before the date.
You can read more about the new law here
. This link is in Swedish.
MDR/EU relatedPosted by Peter Mar 26, 2019 07:49:58
Keeping up with new regulations or guidance can be troublesome or at least take valuable time from your day to day business. New documents releated to MDR are gathered at this page
. Other sources are of coarse linkedin, each authorities web pages, but uou never know for sure if something has been posted or not
MDR/EU relatedPosted by Peter Mar 18, 2019 21:31:34
The first suggested changes to IVDR/MDR are now out for comments. I could not find any bigger changes, but important to review if it effects you! Plan is to get this through Brussels before the EU elections. The suggestion are 125 pages! But dont be scared, it contains all languages! For all Swedes the last 5 pages are for us!Here
you find the MDR propsalHere
tou find the IVDR proposal
MDR/EU relatedPosted by Peter Mar 14, 2019 08:02:19
To be an EU Authorised representative in the new MDR add many new requirements to be meet. In future posts I will go through these.
In addition to what the role is in MDD the representation means a large undertaking of responsibility. In most corporations this are inhouse task that typical someone at the Quality or Regulatory department have. Going forward this most likely will land at the designated persons desk! What will this mean from a personal risk perspective? Right now no one really knowes! Hopefully the law firm speaking about this at the Regulatory Summit
will shed some light, at least for the people in Sweden. The personal risk will probably differs between countries due to the national view and traditions. Clearly something to make some reasearch about before signing up for the role.
Off/on labelPosted by Peter Mar 12, 2019 13:13:41
FTC, FDA and DOJ, is this how it will work with
the new MDR?
Most people working with medical devices that are sold in USA
knows what FDA do and their role in promotion and labelling activities.
Not all people understand Federal Trade Commissions (FTC)
role and escaping or handling FDA does not always mean that you are safe! FTC
are perhaps more known for approving deals from a competition perspective, but
that’s also why they look at advertisement and promotion.
FTCs basic requirements are quite straight forward and can be
found on this link. However even
though it should be simple to follow many companies get into trouble.
FDA warning letter
Department of Justice, DOJ typical gets involved when FTC or
FDA have found issues, A FDA warningletter itself does not mean that you
directly get into trouble but often leads to that DOJ looks into the case. If
DOJ determine that they can claim money back from companies or hospitals they
A typical case:
In case of warning letters due to promotion or advertisement (often
off label claims = not within intended or indication for use) DOJ often can
find wrongly assigned reimbursement codes. If they find this they will claim
that money back. And trust me, if you think FDA can be difficult to handle in a
non-compliance situation, that’s a walk in the park vs DOJ! In the
future I will show several cases in the blog.
One example on this!
The connection to MDR?
In the past promotion and advertisement in Europe have been a national
regulation if regulated at all for B2B type of transactions. With MDR this change
completely, now it will be the law in all EU countries. The rules can be found
in article 7 copied below:
In the labelling, instructions for use, making available,
putting into service and advertising of devices, it shall be prohibited to use
text, names, trademarks, pictures and figurative or other signs that may
mislead the user or the patient with regard to the device's intended purpose,
safety and performance by:
(a) ascribing functions and properties to the device which
the device does not have;
(b) creating a false impression regarding treatment or
diagnosis, functions or properties which the device does not have;
(c) failing to inform the user or the patient of a likely
risk associated with the use of the device in line with its intended purpose;
(d) suggesting uses for the device other than those stated
to form part of the intended purpose for which the conformity assessment was
Who will this apply to?
The rules could apply to most economic operators. The manufacturer, importers
or distributors are probably the ones that most likely could get into trouble
if they do not have this under control. However currently the reimbursement system
does not have the direct relation to intended use why the monetary penalties
most likely will be tied to harm instead. Enforcement will most likely be on
national level due to language used.
MDR/EU relatedPosted by Peter Mar 11, 2019 18:55:26
Enf of February 42 Notified Bodies had applied for MDR, 25 joint assessments have been done and another 4 is scheduled. These figures looks clearly much better than just a month ago and I know that a few other are in the progress of applying.
However more important, when are they approved that companies can start plan for a life after May 25, 2020. Very few of the Notified Bodies communicates where they are in the process and I understand them. No one want to promise to much!
Also folllow Medtech Europe for their updates here